Compare KRT & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRT | ALT |
|---|---|---|
| Founded | 2000 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 492.5M | 415.3M |
| IPO Year | 2021 | N/A |
| Metric | KRT | ALT |
|---|---|---|
| Price | $24.98 | $4.25 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $26.50 | $16.33 |
| AVG Volume (30 Days) | 75.8K | ★ 5.9M |
| Earning Date | 11-06-2025 | 02-26-2026 |
| Dividend Yield | ★ 7.21% | N/A |
| EPS Growth | ★ 6.32 | N/A |
| EPS | ★ 1.50 | N/A |
| Revenue | ★ $453,775,000.00 | $20,000.00 |
| Revenue This Year | $11.37 | N/A |
| Revenue Next Year | $12.29 | N/A |
| P/E Ratio | $16.63 | ★ N/A |
| Revenue Growth | ★ 8.93 | N/A |
| 52 Week Low | $20.61 | $2.90 |
| 52 Week High | $33.89 | $7.73 |
| Indicator | KRT | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 71.24 | 50.65 |
| Support Level | $24.50 | $3.96 |
| Resistance Level | $25.19 | $4.40 |
| Average True Range (ATR) | 0.60 | 0.24 |
| MACD | 0.20 | 0.06 |
| Stochastic Oscillator | 92.83 | 74.48 |
Karat Packaging Inc is engaged in the manufacturing and distribution of disposable products used in restaurants and food service settings. The company operates and evaluates its business as a single reportable segment which encompasses the manufacturing and distribution of a diverse range of single-use food and beverage service products made from materials such as plastic, paper, biopolymer-based, and other compostable forms. The company offers products for the foodservice industry, including food packaging, containers, tableware, cups, lids, cutlery, and straws. These products are available in plastic, paper, biopolymer-based and other compostable forms. Its product line includes a variety of brands such as Tea Zone, Karat, Karat Earth, and Total Clean.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.